Product Description
Mechanisms of Action: S100A9 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Active Biotech AB
Company Location: FREMONT CA 94555
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Scleroderma, General|Scleroderma, Systemic|Lupus Erythematosus, Systemic|Scleroderma, Diffuse
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2011-001667-44 | P2 |
Completed |
Scleroderma, General |
2013-02-15 |
|
| Paquinimod | P2 |
Completed |
Scleroderma, Systemic|Scleroderma, Diffuse|Scleroderma, General |
2013-02-01 |
|
| NCT00997100 | P2 |
Completed |
Lupus Erythematosus, Systemic |
2010-09-01 |
|
| 2009-011245-55 | P2 |
Completed |
Lupus Erythematosus, Systemic |
2010-09-01 |